The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone polymer.

An object of the present invention is to provide an asenapine-containing patch having excellent sustained-release properties while enhancing skin permeability by using a silicone-based pressure-sensitive adhesive base. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, a silicone-based pressure-sensitive adhesive base and a release control agent, and the ratio of the maximum skin permeation rate of asenapine to the minimum skin permeation rate from the time when the maximum skin permeation rate is reached to 24 hours is less than 1.62.

This invention discloses a pharmaceutical formula for arthritis treatment and/or prevention. The formula contains the following raw materials: a selenium-containing inorganic compound and a zinc-containing inorganic compound. The pharmaceutical formula described herein could be manufactured for topic application and provide a faster and safer treatment for various inflammatory joint pains. Pharmacodynamics results show that the invented pharmaceutical formula can significantly reduce the level of inflammatory cytokines in the joint synovial fluid in arthritis rabbit model, and the formulated ointment can achieve better efficacy compared with Voltaren™ (diclofenac) ointment; therefore the proposed formula has promising clinical application.

A multi-phase silicone acrylic hybrid visco-elastic composition prepared by polymerizing an ethylenically unsaturated monomer and a silicon-containing pressure sensitive adhesive composition comprising acrylate or methacrylate functionality in a first solvent in the presence of an initiator, removing the first solvent, and adding a second solvent to form the multi-phase silicone acrylic hybrid visco-elastic composition. Alternatively, a multi-phase silicone acrylic hybrid visco-elastic composition prepared by polymerizing an ethylenically unsaturated monomer and a silicon-containing pressure sensitive adhesive composition comprising acrylate or methacrylate functionality in a first solvent in the presence of an initiator, adding a processing solvent having a higher boiling point than the first solvent, applying heat to selectively remove a majority of the first solvent, removing the processing solvent, and adding a second solvent to form the multi-phase silicone acrylic hybrid visco-elastic composition. The phase arrangement of the multi-phase silicone acrylic hybrid visco-elastic compositions is selectively controlled by selection of the second solvent.

Advantageously, para-chloroaniline (PCA) is minimal in antimicrobial articles prepared according to the method of the invention. A method of forming an antimicrobial article according to the invention comprises steps of: providing a polymerizable composition; incorporating an antimicrobially effective amount of at least one chlorhexidine-containing antimicrobial agent into the polymerizable composition; and, polymerizing the polymerizable composition to form chlorhexidine-containing polymer of the antimicrobial article, wherein processing temperature during the method is less than about 80° C.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of fingolimod.

A method of treating, reducing or preventing bacterial infection in a wound, the method comprising: applying a film on the wound, the film including a biodegradable polymer with bacteriophages dispersed therein, wherein the polymer is a poly (ester amide urea).

A method for improving holding power of an adhesive agent layer in a ropinirole-containing patch comprising a backing layer and the adhesive agent layer, wherein the adhesive agent layer contains at least one selected from the group consisting of ropinirole and a pharmaceutically acceptable salt thereof and an adhesive agent, the method comprising: causing the adhesive agent layer to further contain a sodium salt of carbonic acid.

The invention relates to a transdermal therapeutic system (TTS) for the administration of the active ingredient rotigotine comprising a matrix layer containing rotigotine, one or more non-amine-resistant silicone adhesives in an amount of more than 50% by weight, based on the total weight of the pressure sensitive adhesive of the matrix layer, and paraffin, as well as methods for the preparation thereof. The transdermal therapeutic system according to the invention is particularly suitable for the treatment of the Parkinson disease.

A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance. This mixture forms dispersed deposits in the pressure-sensitive adhesive. The buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.